Overview

Pirfenidone in Adult Hospitalized Patients With COVID-19

Status:
Active, not recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This center intends to conduct a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
Capital Medical University
Treatments:
Pirfenidone